Other Clinical Trial - A Study of INCB050465 in Combination With

Updated 06/21/2024

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

MPN (Myeloproliferative Neoplasms)
Myeloproliferative Disorders
Primary Myelofibrosis

Clinical Trial Details

NCT number	NCT02718300
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Terminated
Phase	Phase 2
Start date	February 8, 2017
Completion date	April 29, 2022

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT03123588` - Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)	Phase 2
	Completed	`NCT01348490` - Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)	Phase 2
	Completed	`NCT02252159` - Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
	Completed	`NCT01633372` - An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis	Phase 2
	Completed	`NCT03144687` - A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis	Phase 2
	Completed	`NCT02953704` - Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
	Completed	`NCT00952289` - COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial	Phase 3
	Active, not recruiting	`NCT03011372` - A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)	Phase 2